Excitement over Jardiance may come at Merck's expense

A recent study suggested that Lilly/BI's Jardiance could be the first diabetes med to cut CVD risk.

By Nicole Gray • Aug. 24, 2015

Rare disease companies' existential challenge: Patient enrollment

Three companies are recruiting patients with Nieman Pick Type C (NPC), a very rare and deadly disease, for clinical trials.

By Nicole Gray • Aug. 21, 2015

Explore the Trendline➔

Vaccine development

Vaccine developers are investing in shots for RSV, influenza and pneumococcal disease in a newly uncertain regulatory climate.

By BioPharma Dive staff

Lilly/BI's Jardiance could be the first diabetes med to cut heart attack, stroke risk

In a large clinical study, people with diabetes who were treated with the drug had significantly fewer cardiac deaths and non-fatal heart attacks or strokes, compared with patients treated with standard of care. 

By Nicole Gray • Aug. 21, 2015

Intarcia's diabetes pump bests Merck's Januvia in head-to-head trial

This could be a big deal for the diabetes market. 

By Nicole Gray • Aug. 19, 2015

Kite Pharma does damage control, quashes drug-induced patient death rumors

Arie Belldegrun, Kite's CEO, reassured investors that negative rumors about an early-stage KTE-C19 trial were false. 

By Nicole Gray • Aug. 18, 2015

Roche's immunotherapy hopeful keeps rolling, this time in phase II lung cancer trial

Atezolizumab is being tested in almost a dozen phase III studies.

By Nicole Gray • Aug. 18, 2015

To reinflate lung portfolio, Glaxo needs Breo to shine where Advair failed

The company hopes that results from a massive trial will set Breo apart from other COPD meds by showing a survival benefit. 

By Sy Mukherjee • Aug. 14, 2015

Avalanche shares continute to fall off a cliff as company ditches eye drug trial

It's back to the preclinical drawing board for the investigational wet AMD drug. 

By Sy Mukherjee • Aug. 14, 2015

AbbVie, Genentech to seek US approval of potential blockbuster leukemia med

AbbVie/Roche's venetoclax is being tested in chronic lymphocytic leukemia (CLL) patients with a gene mutation that slashes survival rates. 

By Sy Mukherjee • Aug. 12, 2015

Clovis & Genentech team up to test out a promising lung cancer combo

The companies want to see if the dual therapy using an EGRF inhibitor and a PD-L1 blocker can be more effective in treating NSCLC patients. 

By Sy Mukherjee • Aug. 12, 2015

Hat trick: AstraZeneca cuts its 3rd cancer drug deal in a week

AZ is now officially on a cancer drug roll with this latest deal with Inovio.

By Randy Lilleston • Aug. 10, 2015

CNS-focused US cannabis patch company raises $42M in IPO

Pennsylvania's Zynerba Pharma plans to move into clinical trials with cannabinoid-laced transdermal patches for treatment of epilepsy and other CNS disorders.

By Nicole Gray • Aug. 6, 2015

A rare case: Young woman with Duchenne's waiting for a cure

The odds of a girl having the disease are one in 50 million. 

By Nicole Gray • Aug. 4, 2015

All-in? AstraZeneca soldiers forward with psoriasis hopeful despite suicide link

And despite the fact that these very concerns led Amgen to back out of its co-development arrangement for the drug with AZ.

By Nicole Gray • Aug. 3, 2015

Finally: Merck Ebola vax triumphs in phase III trial, overcoming logistical nightmare

The investigational vaccine, which the WHO is calling "exciting" and "promising," was apparently 100% effective in protecting patients. And the trial's success is a testament to teamwork and coordination.

By Sy Mukherjee • July 31, 2015

Sanofi's LixiLan aces a late-stage trial, setting up diabetes showdown with Novo

The study combined the investigational compound with Sanofi's flagship insulin product Lantus.

By Nicole Gray • July 30, 2015

Why Pfizer is abandoning its OTC Lipitor program

The fault, in this case, may actually lie with patient compliance. 

By Nicole Gray • July 30, 2015

Want a better placebo effect? Stick to needles over pills

A study published in the Annals of Internal Medicine show that the manner in which a placebo is administered can determine how it works. 

By Nicole Gray • July 29, 2015

EU upholds massive drug ban over alleged CRO data manipulation

Several drug makers approached the European Medicines Agency (EMA) to appeal the suspension—but they were unsuccessful. 

By Nicole Gray • July 28, 2015

2nd gen radiotracers and Alzheimer's diagnosis in the age of early-intervention trials

The AAIC has identified earlier, more precise diagnosis as an important factor in developing drugs to treat early-stage Alzheimer’s. Navidea Biopharmaceuticals is on the forefront of this effort with its next-generation radiotracer, NAV4694.

By Nicole Gray • July 24, 2015

European regulators just announced a massive overhaul of pediatric waivers

As part of a larger effort to increase the number of clinical trials involving children, the European Medicines Agency (EMA) is revoking or modifying most pediatric waivers.

By Nicole Gray • July 24, 2015

BMS and Exelixis make headway against Novartis in kidney cancer

But the Swiss pharma giant is still defending its cancer med Afinitor.

By Nicole Gray • July 23, 2015

A tough setback for AZ as major eye cancer hopeful flunks phase III

At one point, selumetinib was hailed as a potential blockbuster based on strong mid-stage survival data. 

By Nicole Gray • July 23, 2015

Roche renews commitment to R&D of two AD drugs

As the Alzheimer's research community bets bigger on the beta-amyloid theory, Roche has re-committed to two antibody drugs that target amyloid protein.

By Nicole Gray • July 23, 2015

A mixed bag: Biogen's & Lilly's hotly anticipated Alzheimer's data are inconclusive

Both companies' shares fell in early morning trading as the results proved far murkier than many had hoped.

By Sy Mukherjee • July 22, 2015